Inflammation/Immunology

5-LOX/NO-IN-1 (Compound 7e) is a 5-LOX and NO release inhibitor. 5-LOX/NO-IN-1 shows an IC₅₀ of 2.833 μM for 5-LOX. 5-LOX/NO-IN-1 has anti-inflammatory effects.

iNOS-IN-2 (Compound 53) is a potent down-regulator of inducible nitric oxide synthase (iNOS) protein. iNOS-IN-2 effectively inhibits the NO production (IC₅₀=6.4 μM). iNOS-IN-2 has a potential therapeutic effect on chronic inflammation.

N1-Acetyl-5-methoxykynuramine hydrochloride (AMK hydrochloride) is an active metabolite of Melatonin (HY-B0075) with antioxidant activity and blood-brain barrier permeability. N1-Acetyl-5-methoxykynuramine hydrochloride inhibits LPS-induced activation of inducible nitric oxide synthase and COX-2, scavenges ROS, hydroxyl radicals, carbonate radicals and ABTS cation radicals, and protects bovine serum albumin from peroxyl radical-mediated damage. N1-Acetyl-5-methoxykynuramine hydrochloride reduces the increase in cytoplasmic and mitochondrial lipid peroxidation in the substantia nigra and striatum in MPTP (HY-15608)-induced mouse models of Parkinson's disease. N1-Acetyl-5-methoxykynuramine hydrochloride can be used in studies related to Parkinson's disease, metabolism-related diseases and oxidative stress.

The Anti-SCN11a/Nav1.9 Antibody is a CHO-expressed human antibody that targets SCN11a/Nav1.9. The Anti-SCN11a/Nav1.9 Antibody features a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 143.94 kDa. The isotype control for the Anti-SCN11a/Nav1.9 Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).

Anti-IL-13 Antibody (CNTO 607) is a CHO-expressed human antibody that targets IL-13. Anti-IL-13 Antibody (CNTO 607) features a huIgG1 heavy chain and a huλ light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for Anti-IL-13 Antibody (CNTO 607) can be referred to as Human IgG1 kappa, Isotype Control (HY-P99001).

Tremella polysaccharide, MW>1000000, cosmetic grade, one of the fungus polysaccharides, possesses immunity enhancing capabilities. Polysaccharidase has the potential for leukopenia induced by chemotherapy and radiotherapy research.

TRPC4/5-IN-1 is a potent TRP channel 4/5 (TRPC4/5) inhibitor with IC₅₀s of 2.06 μM and 0.54 μM, respectively. TRPC4/5-IN-1 can be used for proteinuric kidney diseases and skin inflammatory diseases research.

Bis(2R,3R)-Orniplabin is an isomer of Orniplabin (HY-122311). Orniplabin (SMTP-7) is a low molecular weight compound that enhances plasminogen-fibrin binding, urokinase-catalyzed plasminogen activation, and urokinase and plasminogen-mediated fibrin degradation. Orniplabin exhibits potential thrombolytic and anti-inflammatory effects. Orniplabin inhibits reactive oxygen species (ROS).

α-Galactosyl FP20 sodium, a TLR-4 agonist, is a vaccine adjuvant.

cGAS-IN-6 (14) is a cGAS inhibitor. cGAS-IN-6’s core structure is a fused imidazole ring system. cGAS-IN-6 can be used for research on autoimmune conditions.

3,6-Dihydroxyindoxazene, an antibiotic can be isolated from C. violaceum, exhibits a selective activity against Gram-negative bacteria.

Semen canavaliae extract (Canavaliae semen extract) is an extract of sword bean (Canavalia Gladiate) with antioxidant and antibacterial activities.

Rhamnocitrin (Standard) is the analytical standard of Rhamnocitrin. This product is intended for research and analytical applications. Rhamnocitrin is an anti-inflammatory and antioxidant agent that targets STIM-1, NFATc3 and MAPK pathways and can scavenge DPPH (IC₅₀=28.38 mM). Rhamnocitrin selectively inhibits oxidative stress and inflammatory responses in vascular endothelial cells and neurons. Rhamnocitrin up-regulates miR-185 to inhibit STIM-1-mediated store-operated calcium entry (SOCE), thereby blocking NFATc3 nuclear translocation and downstream inflammatory factor expression, while inducing heme oxygenase HO-1 expression and regulating the ERK/p38 MAPK pathway, inhibiting antioxidant and pro-inflammatory cytokines (such as IL-6, IL-8) and adhesion molecules (such as ICAM-1, VCAM-1). Rhamnocitrin can be used in the study of endothelial-related inflammatory diseases (such as sepsis, acute lung injury, atherosclerosis) and neuroprotection (such as oxidative damage of PC12 cells).

Ginsenoside C-K (Standard) is the analytical standard of Ginsenoside C-K. This product is intended for research and analytical applications. Ginsenoside C-K, a bacterial metabolite of G-Rb1, exhibits anti-inflammatory effects by reducing iNOS and COX-2. Ginsenoside C-K exhibits an inhibition against the activity of CYP2C9 and CYP2A6 in human liver microsomes with IC50s of 32.0±3.6 μM and 63.6±4.2 μM, respectively.

CKD-712 is an orally active multi-target tetrahydroisoquinoline derivatived and a potent inhibitor of the NF-κB pathway. CKD-712 selectively inhibits MMP-9 with no effect on MMP-2, downregulates the expression of TNF-α, IL-6, cyclin A, cyclin B, CDK-1 and other proteins, and activates the PI3K/Akt signaling pathway. CKD-712 blocks the activation and nuclear translocation of NF-κB, downregulates inflammatory factors and pro-tumor metastatic proteins, and induces G2/M phase arrest in tumor cells and thereby inhibits the invasion of cancer cells. CKD-712 can be used for the research of sepsis, myocardial ischemia-reperfusion injury and non-small cell lung cancer.

SGP8 (IAVPGEVA) is an octapeptide produced by hydrolysis of soybean 11S globulin, which has the effects of regulating lipid metabolism, inflammation and fibrosis. SGP8 (IAVPGEVA) exhibits inhibitory activity against DPP4 and inhibits the JNK-c-Jun signaling pathway, and has the ability to inhibit non-alcoholic steatohepatitis (NASH).

COX-2-IN-27 is a potent and selective COX-2 inhibitor with IC₅₀ values of 13.22, 0.045, 1.67 µM for COX-1, COX-2, 15-LOX, respectively. COX-2-IN-27 shows anti-inflammatory activity.

TRPV1-IN-3 (compound 14) is a TRPV1 inhibitor that can be used for the research of idiopathic pulmonary fibrosis. TRPV1-IN-3 affects the expression of fibrosis markers collagen I and α-SMA by inhibiting the TGF-β/Smads and MAPK pathways, thereby exerting antifibrotic activity in vitro (IC₅₀=0.51 μM). TRPV1-IN-3 significantly inhibits collagen deposition in lung tissue, improves the alveolar structure, and also increases the survival rate of mice with pulmonary fibrosis induced by Bleomycin (HY-108345).

Dinotefuran-NHCO-propionic acid (4) is an antigen. Dinotefuran-NHCO-propionic acid can couple BSA and OVA to obtain the immunogen and the coating antigen (hapten-OVA conjugate) .

Xanthium sibiricum extract is an extract of Xanthium sibiricum that has anti-inflammatory activity.